News
Wegovy maker warns of slower profits as rivals bite
The Danish-maker of Wegovy and Ozempic has warned that its full-year sales and profits will not grow as quickly as expected as more "knock-off" weight-loss drugs emerge. Novo Nordisk's share price tumbled by more than 20% as it cut its outlook and named a new chief executive to replace Lars Fruergaard Jørgensen,
Here are patients’ experiences with Ozempic and Wegovy, and their before-and-after photos. 'It makes food less important' Pepper Schwartz before and after her weight loss. Courtesy Pepper ...
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after losing weight with ...
Ozempic before and after photos show weight loss. Women share what it's like to lose weight with Ozempic and Wegovy, the side effects and cost.
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook ...
If insurance doesn’t cover Ozempic or Wegovy for weight loss, the average monthly price is $1,430, according to Drugs.com. People may need to stop due to side effects, cost or health issues.
The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback